Section I
161 – 170 of 5047
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Aspects of Host-Tumor Interactions and Outcome: Focus on Breast Cancer and Head and Neck Cancer
(2025) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
FEASIBILITY AND POTENTIAL BENEFITS OF MODERATE INTENSITY CYCLING IN PEOPLE LIVING WITH LOWER LIMB LYMPHEDEMA : A PILOT RANDOMIZED CONTROLLED TRIAL
- Contribution to journal › Article
-
Mark
Navigating Immune Landscapes in Ovarian Cancer - Spatial and Genomic Insights into High-Grade Serous and Endometriosis-Associated Histotypes
(2025) In Lund University, Faculty of Medicine Doctoral Dissertation
- Thesis › Doctoral thesis (compilation)
-
Mark
Head and neck lymphedema after radiotherapy − Prevalence, changes and associated factors − a prospective observational cohort study
- Contribution to journal › Article
-
Mark
Applicability of the European Association of Urology 2021 Prognostic Model for Non–muscle-invasive Bladder Cancer in a Swedish Population-based Cohort
- Contribution to journal › Letter
-
Mark
Advances in Risk Management and Screening for Women at Increased Risk of Breast Cancer: The Role of MR Imaging and Personalised Approaches
(2025) In Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine 24(3). p.403-418
- Contribution to journal › Scientific review
-
Mark
A Call for Common Sense in the Use of Molecular Imaging
(2025) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 66(9). p.1500-1501
- Contribution to journal › Letter
-
Mark
Prognostic relevance of CD163+ immune cells in patients with metastatic breast cancer
- Contribution to journal › Article
-
Mark
Identifying prognostic targets in metastatic prostate cancer beyond AR
- Contribution to journal › Article
-
Mark
Statin Therapy in Early Breast Cancer : The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo)Adjuvant Therapy Plus Atorvastatin versus Standard (Neo)Adjuvant Therapy Plus Placebo
- Contribution to journal › Article
